Public markets are letting healthcare startups back in, just not on the terms the last boom set.
After several muted years, biotech and health tech IPOs are picking back up, and founders eyeing a public listing as an exit path are finding the bar has moved considerably since the last cycle.
A reopened window with a much higher sill
More biopharma companies have listed above a $500M valuation in 2026 than in all of 2025, according to Morningstar. JPMorgan's data shows 13 biopharma IPOs raised $5.0B in the first half of 2026 alone, already ahead of every full-year total between 2022 and 2025.
Do the math and that averages roughly $385M per listing, well above what a typical 2022-era biotech IPO raised. For comparison, medtech's IPO activity over the same period was far more selective: just two listings, raising a combined $710M, against $5.0B in medtech venture funding across 164 rounds, showing just how much narrower the public listing path is relative to the private funding still flowing into the sector.
Public markets are now applying a "Rule of 40" standard, combining revenue growth rate and free cash flow margin, alongside stable gross margins of 60-80% and randomised controlled trial-level clinical validation, before a company can realistically list.
Investment bankers describe a "dual-track" pattern becoming standard practice, where late-stage startups prepare an IPO filing and field acquisition offers simultaneously, treating the public listing as leverage rather than the only path.
Selective good news is still good news
A reopened window is genuinely good news, but it is selective good news. The startups clearing the bar are the same kind rewarded in this issue's M&A data: contracted revenue, clear margins and validated clinical outcomes, not simply a growing user base or a compelling founder story.
A company that spent the last two years chasing growth at any cost is likely to find this window closed to it even as headline IPO activity looks strong. The bar isn't just higher, it's a different kind of bar than the one that applied during the last boom.
Benchmark before you need to
Benchmark your own startup against Rule of 40 now, long before any exit conversation, since private acquirers are increasingly using similar criteria even outside a public listing scenario.
Also watch which 2026 IPO candidates actually price successfully versus those that only file, since that gap between filing and pricing is the real signal about investor appetite heading into next year, more so than the raw number of filings itself.
